SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics 2001. CA Cancer J Clin. 2001; 51: 1536.
  • 2
    Ellis MJ, Hayes DF, Lippman ME. Treatment of metastatic breast cancer. In: HarrisJR, LippmanME, MorrowM, et al., editors. Diseases of the breast. Philadelphia: Lippincott Williams and Wilkins, 2000: 749.
  • 3
    Esteva FJ, Valero V, Pusztai L, et al. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist. 2001; 6: 133146.
  • 4
    Ringel I, Horwitz SB. Studies with RP 56976 (taxotere), a semisynthetic analogue of taxol. J Natl Cancer Inst. 1991; 83: 288291.
  • 5
    Diax JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry and competition. Biochemistry. 1993; 32: 27472755.
  • 6
    Schmidinger M, Budinsky AC, Wenzel C, et al. Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a mulitcenter, community-based feasibility trial. Cancer Chemother Pharmacol. 2001; 47: 5762.
  • 7
    Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol. 1999; 17: 23412354.
  • 8
    Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol. 1999; 17: 14131424.
  • 9
    Kreis W, Budman D, Fetten J, et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol. 1999; 10: 3338.
  • 10
    Williams JF, Muenchen HJ, Kamradt JM, et al. Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study. Prostate. 2000; 44: 275278.
  • 11
    Bjork P, Forgren B, Gustafsson J-A, et al. Partial characterization and quantitation of a human prostatic estramustine binding protein. Cancer Res. 1982; 39: 51555164.
  • 12
    Bjork P, Ferno M, Ferno M, et al. Expression and partial characterization of estramustine binding protein in human breast cancer and malignant melanoma. Anticancer Res. 1991; 11: 11731182.
  • 13
    von Schoultz E, Bergenheim T, Grankvist K, et al. Estramustine binding protein in human brain tumor tissue. J Neurosurg. 1989; 14: 2743.
  • 14
    Stearns M, Tew K. Antimicrotubule effects of estramustine, an antiprostate tumor drug. Cancer Res. 1985; 45: 38913897.
  • 15
    Wallin M, Deinum J, Hartley-Asp B. Estramustine phosphate inhibits microtubule assembly by binding to the microtubule associated proteins. Ann NY Acad Sci. 1986; 466: 423425.
  • 16
    Panda D, Miller HP, Islam K, Wilson L. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action. Proc Natl Acad Sci USA. 1997; 94: 1056010564.
  • 17
    Yang CPH, Shen H, Horwitz SB. Modulation of the function of P-glycoprotein by estramustine. J Natl Cancer Inst. 1994; 86: 723725.
  • 18
    Kreis W, Budman D, Fetten J, et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol. 1999; 10: 3338.
  • 19
    Petrylak D, MacArthur R, O'Connor J, et al. Phase I trial of docetaxel with estramustine in androgen independent prostate cancer. J Clin Oncol. 1999; 17: 958967.
  • 20
    Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol. 2001; 19: 25092516.
  • 21
    Simon R. Optimal two-stage designs for Phase II clinical trials. Control Clin Trials. 1989; 10: 110.
  • 22
    Alexander NC, Hancock AK, Masood MB, et al. Estracyst in advanced carcinoma of the breast: a Phase II study. Clin Radiol. 1979; 30: 139147.
  • 23
    Wada T, Morikawa E, Houjou T, et al. Clinical evaluation of estramustine phosphate in the treatment of patients with advanced breast cancers. Jpn J Cancer Chemother. 1990; 17: 19011904.
  • 24
    Valero V. Docetaxel as a single-agent therapy in metastatic breast cancer: clinical efficacy. Semin Oncol. 1997; 24(4 Suppl 13 ): S13-1S13-18.
  • 25
    Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995; 13: 26432655.
  • 26
    Ravdin PM, Burris HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol. 1995; 13: 28792885.
  • 27
    Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995; 13: 28862894.
  • 28
    Levine M, Hirsch J, Gent M, et al. Double blind randomized trial of a very low dose wafarin for prevention of thromboembolism in Stage IV breast cancer. Lancet. 1997; 343: 886889.
  • 29
    Levin MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost. 1997; 78: 133136.